Nabla secures $70M to streamline EHR workflows with agentic AI

Nabla, the clinical artificial intelligence company that started by automating medical documentation, has raised $70 million in Series C funding as it pivots toward a more ambitious vision: AI agents that can take actions within electronic health records and adapt to different healthcare settings.

HV Capital led the financing with participation from Highland Europe and Cathay Innovation, bringing the company’s total funding to $120 million. The round comes as Nabla reports explosive growth, with revenue increasing fivefold over the past six months and its AI assistant now supporting more than 85,000 clinicians handling 20 million patient encounters annually.

Paris-based founders Alex LeBrun, Delphine Groll, and Martin Raison initially focused Nabla on using AI to listen to patient conversations and automatically generate clinical notes. But the company now expands what it calls an “agentic” approach, where AI doesn’t just document care but actively initiates actions within complex clinical workflows.

“We’re going even deeper into clinical workflows while continuing to offer a highly customizable assistant that works across specialties,” LeBrun, the company’s CEO, said in a statement. “Clinicians already trust our accuracy and speed, and this funding allows us to expand that impact by embedding intelligent support directly into care delivery. We see a future where AI not only documents care, but actively drives efficiency by executing actions within complex clinical workflows and environments.”

Major health systems including CVS Health, Children’s Hospital Los Angeles, Denver Health, and University of Iowa Health Care now use the company’s technology. Real-world studies from these partners show Nabla’s technology can cut documentation time by more than half while reducing clinician burnout and boosting patient satisfaction scores by 15 points.

Nabla centers its expansion plans on three key areas: a proactive coding agent that will improve real-time support for medical coding and compliance; a context-aware agent that uses historical patient data to suggest documentation and initiate EHR commands; and specialized agents tailored for nurses and other frontline healthcare workers.

The company’s growth trajectory reflects broader momentum in healthcare AI, particularly ambient documentation tools that promise to reduce administrative burden on clinicians. Nabla competes with companies like Nuance (owned by Microsoft), Abridge, and Suki in this space, but distinguishes itself through deep EHR integrations and support for 35 languages.

“What stands out just as much as the speed of adoption is the partnership,” said Dr. James Blum, chief health information officer at University of Iowa Physicians. “Nabla listens, adapts, and builds with us. That kind of collaboration drives meaningful change.”

The company has built its technology around a domain-specific large language model that trains on clinical data, processing more than 30 billion tokens monthly. This scale enables continuous refinement while maintaining the accuracy and reliability that health systems require for widespread deployment.

Nabla’s platform integrates with major EHRs including Epic, Cerner, athenahealth, and NextGen, and the company emphasizes a privacy-first approach to handling sensitive medical data. The company also participates as a member of the Coalition for Health AI, helping shape governance standards for clinical AI applications.

The funding round impressed investors with its speed and oversubscription, according to Alexander Joel-Carbonell, partner at HV Capital. “I’ve rarely seen a technology scale this quickly, earn this level of trust, and deliver such exceptional accuracy,” he said.

With healthcare organizations facing increasing pressure to improve efficiency while maintaining quality of care, Nabla’s expansion into workflow automation represents a significant bet on AI’s ability to transform clinical operations beyond just documentation. The company faces the challenge of executing this broader vision while maintaining the accuracy and reliability that have driven its rapid adoption to date.

The Series C funding will support product development across Nabla’s expanded platform, as well as continued geographic expansion and deeper integration capabilities with health system partners.